Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
26 sept. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis The REGENCY study met its primary endpoint, demonstrating...
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
24 sept. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers...
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
23 sept. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
19 sept. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
16 sept. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's officeThis approval is backed by a decade of proven safety...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
13 sept. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq1,2New subcutaneous (SC)...
Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen
10 sept. 2024 10h00 HE
|
F. Hoffmann-La Roche Ltd
Das innovativste Forschungs- und Entwicklungszentrum der Schweiz unterstreicht Roches langfristige Investitionen in den wissenschaftlichen Fortschritt, um den Bedürfnissen der Patienten gerecht zu...
Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
10 sept. 2024 10h00 HE
|
F. Hoffmann-La Roche Ltd
Switzerland’s most innovative research and development center underscores Roche’s long-term investment in scientific advancement to meet patient needsThe new center will simplify and increase...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
04 sept. 2024 02h00 HE
|
F. Hoffmann-La Roche Ltd
New Phase II data show vast majority of patients experiencing no relapses or disability progressionFenebrutinib suppressed acute and chronic MRI lesionsFenebrutinib’s safety profile was consistent...
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
27 août 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregiversApproval...